Physician profile
Demetrios S Theodoropoulos
NPI 1326299488
$5,167.13
in general payments reported to CMS, 2019-2025
23 companies · $764 in 2025
The $764 reported for 2025 was less than what a typical Clinical & Laboratory Immunology (Allergy & Immunology) provider received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $218 · 2021: $223 · 2022: $1,129 · 2023: $1,186 · 2024: $969 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,116.91 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $775.03 | 2019-2024 | |
| Amgen INC. | $372.91 | 2022-2024 | Tezspire |
| Glaxosmithkline, LLC. | $272.08 | 2019-2023 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $242.53 | 2025 | Neffy |
| Grifols USA, LLC | $207.41 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $171.87 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $169.38 | 2019-2024 | Dupixent |
| Biocryst US Sales Co., LLC | $119.21 | 2022-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $101.96 | 2019-2022 | |
| Pharming Healthcare, INC. | $99.10 | 2022-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $95.06 | 2021-2022 | |
| Optinose US, INC. | $89.32 | 2019-2024 | |
| Octapharma USA, INC. | $85.16 | 2023-2024 | Cutaquig |
| Incyte Corporation | $44.05 | 2023-2024 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $39.04 | 2025 | |
| Shire North American Group INC | $36.22 | 2019 | |
| Genentech USA, INC. | $35.23 | 2022-2024 | Xolair |
| Pfizer INC. | $28.51 | 2021-2023 | |
| Galderma Laboratories, L.P. | $18.52 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.97 | 2022 | |
| Alk-Abello, INC | $15.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demetrios Theodoropoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.